• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Introduction to 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6)

7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one, identified by the chemical compound code CAS No. 709652-84-6, represents a significant compound in the realm of pharmaceutical and medicinal chemistry. This heterocyclic scaffold, featuring a brominated pyrazinone core, has garnered considerable attention due to its structural versatility and potential biological activities. The presence of both the bromo substituent and the dihydropyrido system makes it a promising candidate for further exploration in drug discovery and development.

The molecular structure of 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one encompasses a fused bicyclic system, which is a common motif in many bioactive molecules. The pyrazinone ring, characterized by its nitrogen-rich environment, contributes to its ability to interact with various biological targets. Specifically, the bromo atom at the 7-position introduces a point of reactivity that can be exploited for further functionalization, enabling the synthesis of derivatives with tailored properties.

In recent years, there has been growing interest in exploring the pharmacological potential of compounds with similar scaffolds. The dihydropyrido system, in particular, has been associated with various biological activities, including anti-inflammatory, antiviral, and anticancer effects. This has prompted researchers to investigate derivatives of this class for their therapeutic applications. The compound 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6) stands out as a key intermediate in this context.

One of the most compelling aspects of this compound is its synthetic accessibility. The presence of the bromo group allows for facile coupling reactions with a variety of nucleophiles, facilitating the construction of more complex molecules. This feature is particularly valuable in medicinal chemistry, where rapid and efficient synthesis is often required to screen large libraries of compounds for biological activity. Additionally, the dihydropyrido core provides a stable framework that can be modified without compromising the overall integrity of the molecule.

Recent studies have highlighted the importance of heterocyclic compounds in drug discovery. These molecules often exhibit high binding affinity and selectivity towards biological targets, making them ideal candidates for therapeutic intervention. The 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6) is no exception and has been investigated for its potential role in modulating various cellular processes.

The bromine atom at the 7-position of the pyrazinone ring is particularly noteworthy due to its ability to participate in electrophilic aromatic substitution reactions. This reactivity allows for the introduction of additional functional groups at strategic positions within the molecule, enhancing its pharmacological profile. For instance, palladium-catalyzed cross-coupling reactions can be employed to introduce aryl or vinyl groups at various positions along the scaffold.

In addition to its synthetic utility, 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6) has shown promise in preliminary biological assays. These studies have indicated that derivatives of this compound may exhibit inhibitory activity against certain enzymes and receptors involved in disease pathways. For example, modifications at the 3 and 4 positions of the dihydropyrido ring have been explored to enhance binding affinity towards specific targets.

The development of novel therapeutic agents relies heavily on innovative synthetic methodologies and structural modifications. The versatility of 7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6) makes it an attractive scaffold for such endeavors. By leveraging its reactive sites and exploring different synthetic strategies, researchers can generate a diverse array of derivatives with unique pharmacological properties.

The integration of computational chemistry techniques has further accelerated the discovery process for compounds like this one. Molecular modeling studies can predict how modifications to the structure will affect binding interactions with biological targets. This approach allows for rational design of derivatives with enhanced potency and selectivity.

Future research directions may focus on optimizing synthetic routes to improve yield and scalability while maintaining structural integrity. Additionally, exploring new functionalization strategies could lead to novel derivatives with improved pharmacokinetic profiles and reduced toxicity.

In conclusion,7-Bromo-3,4-dihydropyrido2,3-bpyrazin-2(1H)-one (CAS No. 709652-84-6) represents a valuable asset in pharmaceutical research due to its structural features and synthetic flexibility. Its potential as a lead compound or intermediate for further development underscores its importance in advancing drug discovery efforts across multiple therapeutic areas.

• 91673-75-5(Pyrido[2,3-b]pyrazine-2,3-dione,6-amino-1,4-dihydro-)
• 2067-84-7(1H,2H,3H,4H-pyrido[2,3-b]pyrazine-2,3-dione)
• 52333-31-0(7-Bromo-1,2,3,4-tetrahydropyrido2,3-bpyrazine)
• 168123-82-8(7-bromo-1H,2H,3H,4H-pyrido[2,3-b]pyrazine-2,3-dione)
• 957198-15-1(7-Bromo-1,2-dihydropyrido2,3-bpyrazin-3(4h)-one)
• 896161-09-4(2-Acetamido-5-amino-3-bromopyridine)
• 67074-78-6(Pyrido[2,3-b]pyrazin-2(1H)-one, 3,4-dihydro-)
• 67074-79-7(3,4-dihydro-1-methyl-Pyrido[2,3-b]pyrazin-2(1H)-one)
• 1142192-65-1(1-(7-Bromo-4-methyl-3,4-dihydropyrido2,3-b-pyrazin-1(2h)-yl)-2,2-dimethylpropan-1-one)
• 620175-60-2(ACETAMIDE, 2-[(5-BROMO-2-PYRIDINYL)AMINO]-N-METHYL-)